Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 162

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 162
---
 2023 and December 31, 2022, there were warrants outstanding to purchase an aggregate    
 of 3,090,787 shares of common stock of the Company. As of December 31, 2023, these warrants are exercisable at a weighted average price  
 of $12.50 and their weighted average remaining contractual term is approximately 3.0 years.                                              |

| b. | On                                                                                                
 June 1, 2022, the Company entered into an At The Market Offering Agreement (the “ATM              
 Agreement”) which was amended on September 1, 2022 with H.C. Wainwright & Co.,                    
 LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and                   
 sell, from time to time through Wainwright, shares of the Company’s common stock, par             
 value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The                    
 issuance and sale of common stock by the Company under the ATM                                    
 Agreement is being made pursuant to the Company’s effective “shelf”                               
 registration statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective 
 on September 9, 2022. In March 2024, The Company sold                                             
 137,836 shares of the Company’s common stock for an aggregate gross proceeds                      
 of $0.3 million. The Company’s effective “shelf” registration                                     
 statement on Form S-3 is under General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule.     |

| c. | On December, 22, 2022, the                                                                                                           
 Company entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln                   
 Park”), which provides that, upon the terms and subject to the conditions and limitations in the Purchase Agreement, Lincoln         
 Park is committed to purchase up to an aggregate of $20.0 million of the Company’s shares of common stock over a 36-month            
 period (unless extended to a 48-month period pursuant to the Purchase Agreement). The Company will control the timing and amount of  
 sales of the Company’s shares to Lincoln Park. As consideration for Lincoln Park’s irrevocable commitment to purchase                
 shares of the Company’s common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase       
 Agreement, upon execution of the Purchase Agreement, the Company (i) issued to